Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]

£1.01M GBP

Funder	National Institute for Health Research
Recipient Organization	University of Liverpool
Country	United Kingdom
Start Date	Feb 10, 2021
End Date	Aug 03, 2021
Duration	174 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133505`

Grant Description

To appraise the clinical and cost effectiveness of nivolumab in combination with chemotherapy within its marketing authorisation for untreated advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma.